pharma · Weight Loss · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) · VKTX
Viking Therapeutics
Viking Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker VKTX. Primary therapeutic focus areas include Weight Loss, Adrenomyeloneuropathy Form (AMN) of X-linked Adrenol
San Diego, USA HQ
2012 Founded
60 Employees
Public company Type
VKTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2012
- Employees
- 60
- Programs
- 6
- Drugs
- 3
- Patents
- 15
VK2735
Phase 3 · small molecule · Weight Loss
VK2735 for Weight Loss is a Phase 3 program (small_molecule) at Viking Therapeutics with 4 ClinicalTrials.gov record(s).
Internal code VK2735-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Viking Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Weight Loss
- Status
- active
- Trials
- 4